Glufosfamide

DB06177InvestigationalSmall molecule

Investigated for use/treatment in pancreatic cancer, solid tumors, breast cancer, colorectal cancer, brain cancer, lung cancer, ovarian cancer, and sarcoma.

Primary indication: Investigated for use/treatment in pancreatic cancer, solid tumors, breast cancer, colorectal cancer, brain cancer, lung cancer, ovarian cancer, and sarcoma.Curator reviewed
Formula / weight: C₁₀H₂₁Cl₂N₂O₇P · 383.16 g/mol (avg)
Code names: D-19575

Resolves to

Compound

UNII1W5N8SZD9ACAS132682-98-5ChEMBLCHEMBL2107143

Structure

InChIKeyPSVUJBVBCOISSP-SPFKKGSWSA-NSMILESOC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O

Transporters

Q9NY91SLC5A4

What you can answer from here — as of July 03, 2026

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of Glufosfamide, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account